TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Treatment outcome of pituitary diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: olfactory functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Reach Steady State
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve (AUC) From Time Zero (AUC0) to the Time of the Last Quantifiable Plasma Sample (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients experiencing Grade 3-5 Treatment Related Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: plasma Cmax of gabapentin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt of gabapentin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of the Biosynex Covid-19 Ag BSS rapid antigenic test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cotinine rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of AZD8701
Endpoint domain: Adverse events/effects
Primary endpoint: Objective Response Rate according to RECIST 1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean Score of Investigator Global Assessment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Subjects With <15% or ≥15% Decline in Forced Expiratory Volume in 1 Second [FEV1]
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Alive and free of respiratory failure at day 28
Endpoint domain: Mortality/survival
Primary endpoint: Change in Thirty second chair-stand test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Stair-climb test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Timed up-and-go test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Six minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in physical activity measurements using activPAL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective response rate (complete or partial response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance rate of the physical activity sessions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Compliance rate of the phone calls
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Compliance rate of the activity tracker
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in moderate-to-vigorous physical activity participation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Sum of pain intensity difference (SPID)6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Assessment of Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abdominal rSO2 values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of evaluable telemedical oculomotor examinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Image Quality of Aurora camera
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax: Maximum Observed Plasma Concentration of Tasurgratinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-t): Area Under the Plasma Concentration versus Time Curve from Time 0 to Time of Last Quantifiable Concentration of Tasurgratinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-inf): Area Under the Plasma Concentration versus Time Curve from Time 0 to Infinity of Tasurgratinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pelvic Floor Distress Inventory PFDI-20
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pelvic Floor Impact Questionnaire PFIQ
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Female Sexual Dysfunction Index FSFI
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 3-D Accelerometric and gyroscope variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants who experience an adverse event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants who discontinue study treatment due to an AE
Endpoint domain: Adverse events/effects
Primary endpoint: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Grades 1-5 Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximal tendon pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: grade 3-5 toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in the number of actinic keratoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Fasting Glucose Tolerance (FGT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glucose Tolerance (GT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HB-A1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants With a Confirmed Best Overall Response of Complete Response (CR) or Partial Response (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants With a Confirmed Best Overall Response of CR, PR, or Stable Disease (SD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Morbidity from respiratory infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Morbidity from diarrheal infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Changes in facial hard and soft tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in linguistic performance and competence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Core Outcome Measures Index - Hernia (COMI - Hernia) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Compliance to self-collection for detection of HPV-DNA
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Days of illness symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of illness episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Day care absenteeism
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Parental work absenteeism
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes of skin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Duration of patient's caught
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of Forearm Rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of people interested in using toothpaste
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PP knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-efficacy for using PPs
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-efficacy for health decision making
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Plasmatic dosages
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep Condition Indicator
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: incidence of stroke, leak, thrombus and death
Endpoint domain: Mortality/survival
Primary endpoint: procedural complications
Endpoint domain: Adverse events/effects
Primary endpoint: Difference in duration of AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Complication in patient with piccline
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of patient recruitment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of patient randomization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of data collection procedures
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Changes in the score of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse events of grade 3 or 4
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of Alpha-Mannosidosis disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Naloxone uptake
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Naloxone use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Overdose risk behaviors
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment-related Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Withdrawals due to Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in pacemaker sensing thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in pacing thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in telemetry interference or pacemaker inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of Grade ≥ 1 Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in CD4 T Cell-Associated Proviral HIV-1 DNA From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cleft lip palate surgical knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cleft lip palate surgical confidence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: hospitalization day
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Gross oxygen consumption (VO2) at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gross heart rate (HR) at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic Equivalent of Task (MET) at begin of walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic goals achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time up and Go test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active knee extension test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sit and reach Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fecal gut microbiota composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of misclassification on day 14 based on heartburn
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Effectiveness of liposomal doxorubicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tumor margin status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean Absolute Relative Difference (MARD) Between BGMS Results and Reference Method Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve (AUC0-12h,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum measured concentration (Cmax,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Plasma Glucose Area Under the Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum Plasma Concentration of Norethindrone With Colchicine at Steady State (Cmax, ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration of Norethindrone With Placebo at Steady State (Cmax, ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration of Ethinyl Estradiol With Colchicine at Steady State (Cmax, ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration of Ethinyl Estradiol With Placebo at Steady State (Cmax, ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dosing compliance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to Establish Full Enteral Feeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change From Baseline in Total Score on Yale-Brown Obsessive Compulsive Scale (Y-BOCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunologic Response (IFNƴ production from CD8+ T cells)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Participants' level of mood and anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Accuracy of Pulse Oximeter Sensor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physicians' knowledge and behavior regarding chronic Hepatitis B Virus infection
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Chalder Fatigue Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Mean difference in levels of Polyamine spermine, putrescine, and spermidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurable blinking character
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimal Disease Residual (MRD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With ACR20 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perioperative changes in blood gases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time necessary for PRO completion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Completion rate among eligible patients
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean Change From Baseline in Total Nasal Symptom Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tobacco 7-day point prevalence abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in bDMARDS knowledge and skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Severity of Covid-19 infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Neuropsychological function test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Veterans Rand 12-item Health Survey Score (VR-12)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Biomarkers for efficacy evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Tomographic parameters of keratoconus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC) for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of women who use HERC
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety of ZMappTM
Endpoint domain: Adverse events/effects
Primary endpoint: Serum pharmacokinetics of ZMappTM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-day point prevalent smoking abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily Time in Moderate/Vigorous Physical Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of AIN457 in dermal interstitial fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-Month Complete Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of AM404 in cerebrospinal fluid (CSF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of representative biopsies from tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of Subjects Identified as Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Urinary Biomarkers of Acute Kidney Injury (AKI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Surgical planning effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rates of infant sleep problems
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in perioperative opioid consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute neuropathic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of achieving planned chemotherapy administration on time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Healthcare Workers With Symptomatic COVID Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Worst pain intensity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Asthma controller medication adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Quantification of Delphinidin-3-O-glucoside and Cyanidin-3-O-sambubioside
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantification of gallic acid and protocatechuic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ferric reducing ability of plasma (FRAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serious Adverse Device Effects (SADEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Signal-to-Noise Ratio percentage (SNR%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of patients who suffer from delirium postoperatively
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Fat Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recommended phase 2 dose (RP2D) of chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in reaction time during memory testing during fMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in reaction time during executive function testing during fMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in accuracy during memory testing during gait task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in reaction time during executive function testing during gait task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Standards Uptakes Values (SUVr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Supporting Alveolar Mucosa Status_3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Supporting Alveolar Mucosa Status_6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Color Stability_3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak concentration (ng/mL) of TA-8995
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve (mg/L・hr) of TA-8995
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term safety of Zoledronic Acid
Endpoint domain: Adverse events/effects
Primary endpoint: area under the plasma concentration-time curve from 0 to the last measurable concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety of vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Change in HAV characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HAV patency rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in frequency and severity of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in hematology, coagulation and clinical chemistry parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Overall Response Rate (ORR) at Week 12 for Non-CLL Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes